Update on PSMA-based Prostate Cancer Imaging

Overview

Journal Semin Nucl Med

Specialty Nuclear Medicine

Date 2024 Nov 3

PMID 39490335

Authors

Esther Mena

Liza Lindenberg

Peter L Choyke

Affiliations

Soon will be listed here.

Abstract

The increased use of prostate-specific membrane antigen (PSMA) based PET imaging for prostate cancer (Pca) detection has revolutionized the clinical management of Pca, with higher diagnostic sensitivity for extraprostatic disease and increasing clinical utility across different stages of the disease. The integration of PSMA PET imaging into clinical guidelines and consensus documents reflects its growing importance in the personalized management of Pca. This review of recent literature highlights the rapid evolution of PSMA PET into the mainstream of staging and restaging and the decreasing reliance on conventional imaging modalities. This comprehensive review serves as a resource for clinicians and researchers involved in the domains of Pca diagnosis and management.

Citing Articles

Comparison of Cu-DOTA-PSMA-3Q and Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging.

Liu H, Zhang X, Zhang J, Pan Y, Wen H, Xu X Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39954062 DOI: 10.1007/s00259-025-07131-3.

Diagnostic Ability of Quantitative Parameters of Whole-Body Bone SPECT/CT Using a Full-Ring 360° Cadmium-Zinc-Telluride Camera for Detecting Bone Metastasis in Patients with Prostate Cancer.

Yoo I, Hong S, Lee S, Yang H, Kim K, Kim S Diagnostics (Basel). 2024; 14(23).

PMID: 39682622 PMC: 11639772. DOI: 10.3390/diagnostics14232714.

References

Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts J . 3-Year Freedom from Progression After Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. J Nucl Med. 2019; 61(6):866-872. DOI: 10.2967/jnumed.119.235028. View

Hope T, Eiber M, Armstrong W, Juarez R, Murthy V, Lawhn-Heath C . Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021; 7(11):1635-1642. PMC: 8446902. DOI: 10.1001/jamaoncol.2021.3771. View

Woo S, Ghafoor S, Becker A, Han S, Wibmer A, Hricak H . Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J Hybrid Imaging. 2021; 4(1):16. PMC: 8218057. DOI: 10.1186/s41824-020-00085-9. View

Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H . Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. Radiother Oncol. 2023; 184:109678. DOI: 10.1016/j.radonc.2023.109678. View

Hofman M, Emmett L, Sandhu S, Iravani A, Joshua A, Goh J . [Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021; 397(10276):797-804. DOI: 10.1016/S0140-6736(21)00237-3. View

Morris M, Rowe S, Gorin M, Saperstein L, Pouliot F, Josephson D . Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021; 27(13):3674-3682. PMC: 8382991. DOI: 10.1158/1078-0432.CCR-20-4573. View

Ghezzo S, Mapelli P, Samanes Gajate A, Palmisano A, Cucchiara V, Brembilla G . Diagnostic accuracy of fully hybrid [Ga]Ga-PSMA-11 PET/MRI and [Ga]Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial. Eur J Nucl Med Mol Imaging. 2023; 51(3):907-918. DOI: 10.1007/s00259-023-06483-y. View

Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T . PSA-Stratified Performance of F- and Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2016; 58(6):947-952. DOI: 10.2967/jnumed.116.185538. View

Cornford P, van den Bergh R, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J . EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024; 86(2):148-163. DOI: 10.1016/j.eururo.2024.03.027. View

10.

Falagario U, Abbadi A, Remmers S, Bjornebo L, Bogdanovic D, Martini A . Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy. JAMA Netw Open. 2023; 6(9):e2332900. PMC: 10495864. DOI: 10.1001/jamanetworkopen.2023.32900. View

11.

Zang S, Jiang C, Zhang L, Fu J, Meng Q, Wu W . Deep learning based on 68Ga-PSMA-11 PET/CT for predicting pathological upgrading in patients with prostate cancer. Front Oncol. 2024; 13:1273414. PMC: 10800856. DOI: 10.3389/fonc.2023.1273414. View

12.

Liu J, Cundy T, Woon D, Desai N, Palaniswami M, Lawrentschuk N . A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer. BJU Int. 2024; 134(5):714-722. DOI: 10.1111/bju.16412. View

13.

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

14.

Celli M, De Giorgi U, Caroli P, Di Iorio V, Fantini L, Rossetti V . Clinical value of negative Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020; 48(1):87-94. DOI: 10.1007/s00259-020-04914-8. View

15.

Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S . Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2013; 65(6):1034-43. DOI: 10.1016/j.eururo.2013.08.013. View

16.

Bauckneht M, Lanfranchi F, Albano D, Triggiani L, Linguanti F, Urso L . Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study). J Nucl Med. 2024; 65(8):1202-1209. PMC: 11294064. DOI: 10.2967/jnumed.124.267586. View

17.

Meijer D, Eppinga W, Mohede R, Vanneste B, Meijnen P, Meijer O . Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. Eur Urol Oncol. 2022; 5(2):146-152. DOI: 10.1016/j.euo.2022.01.001. View

18.

Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J . Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer. Cancer Imaging. 2024; 24(1):117. PMC: 11363643. DOI: 10.1186/s40644-024-00752-1. View

19.

Kostyszyn D, Fechter T, Bartl N, Grosu A, Gratzke C, Sigle A . Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. J Nucl Med. 2020; 62(6):823-828. PMC: 8729869. DOI: 10.2967/jnumed.120.254623. View

20.

Mun Chow K, So W, Lee H, Lee A, Yap D, Takwoingi Y . Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and.... Eur Urol. 2023; 84(1):36-48. DOI: 10.1016/j.eururo.2023.03.001. View